Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine k...

Full description

Bibliographic Details
Main Authors: Ting-Ting Yang, Wei-Hao Chen, Yan-Min Zhao, Hua-Rui Fu, He Huang, Ji-Min Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
hematopoietic stem cell transplantation
EBV-negative
posttransplant lymphoproliferative disorder
lymphoma
zanubrutinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.672052/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.672052/full

Similar Items